1 Conti, F., Morelon, E. & Calmus, Y. Immunosuppressive therapy in liver transplantation. J Hepatol39, 664-678, doi:10.1016/s0168-8278(03)00428-8 (2003).
2 Coutinho, A. E. & Chapman, K. E. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol335, 2-13, doi:10.1016/j.mce.2010.04.005 (2011).
3 Kamen, D. L. & Zollars, E. S. Corticosteroids in Lupus Nephritis and Central Nervous System Lupus. Rheum Dis Clin North Am42, 63-73, viii, doi:10.1016/j.rdc.2015.08.008 (2016).
4 Mathian, A. et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis79, 339-346, doi:10.1136/annrheumdis-2019-216303 (2020).
5 Mullerova, H., Cockle, S. M., Gunsoy, N. B., Nelsen, L. M. & Albers, F. C. Clinical characteristics and burden of illness among adolescent and adult patients with severe asthma by asthma control: the IDEAL study. J Asthma, 1-12, doi:10.1080/02770903.2019.1708095 (2020).
6 Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H. & Foster, C. S. Long-term side effects of glucocorticoids. Expert Opin Drug Saf15, 457-465, doi:10.1517/14740338.2016.1140743 (2016).
7 McDonough, A. K., Curtis, J. R. & Saag, K. G. The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol20, 131-137, doi:10.1097/BOR.0b013e3282f51031 (2008).
8 Liu, D. et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol9, 30, doi:10.1186/1710-1492-9-30 (2013).
9 van der Goes, M. C., Jacobs, J. W. & Bijlsma, J. W. The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects. Arthritis Res Ther16 Suppl 2, S2, doi:10.1186/ar4686 (2014).
10 Best, J. H., Kong, A. M., Unizony, S., Tran, O. & Michalska, M. Risk of Potential Glucocorticoid-Related Adverse Events in Patients with Giant Cell Arteritis: Results from a USA-Based Electronic Health Records Database. Rheumatol Ther6, 599-610, doi:10.1007/s40744-019-00180-9 (2019).
11 Gale, S. et al. Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK. Rheumatol Ther5, 327-340, doi:10.1007/s40744-018-0112-8 (2018).
12 del Rincon, I., Battafarano, D. F., Restrepo, J. F., Erikson, J. M. & Escalante, A. Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol66, 264-272, doi:10.1002/art.38210 (2014).
13 van Staa, T. P. et al. A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. QJM98, 191-198, doi:10.1093/qjmed/hci029 (2005).
14 Amiche, M. A. et al. Impact of cumulative exposure to high-dose oral glucocorticoids on fracture risk in Denmark: a population-based case-control study. Arch Osteoporos13, 30, doi:10.1007/s11657-018-0424-x (2018).
15 Balasubramanian, A. et al. Glucocorticoid Exposure and Fracture Risk in a Cohort of US Patients With Selected Conditions. J Bone Miner Res33, 1881-1888, doi:10.1002/jbmr.3523 (2018).
16 Dixon, W. G. et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis71, 1128-1133, doi:10.1136/annrheumdis-2011-200702 (2012).
17 Florance, J., Hemke, R., Chang, C. Y., Torriani, M. & Bredella, M. A. Effects of intra-articular corticosteroid injections on lumbar trabecular density. Skeletal Radiol49, 787-793, doi:10.1007/s00256-019-03362-2 (2020).
18 Mebrahtu, T. F. et al. Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England. J Clin Endocrinol Metab, doi:10.1210/jc.2019-00153 (2019).
19 Palmsten, K. et al. Oral corticosteroid use during pregnancy and risk of preterm birth. Rheumatology (Oxford)59, 1262-1271, doi:10.1093/rheumatology/kez405 (2020).
20 van Vollenhoven, R. F. et al. Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials. Arthritis Rheumatol68, 2184-2192, doi:10.1002/art.39682 (2016).